Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis.
Journal: 2019/November - ACR open rheumatology
ISSN: 2578-5745
Abstract:
Metabolic syndrome (MetS) prevalence in early rheumatoid arthritis (ERA) is conflicting. The impact of sex, including menopause, has not been described. We estimated the prevalence and factors associated with MetS in men and women with ERA.A cross-sectional study of the Canadian Early Arthritis Cohort (CATCH) was performed. Participants with baseline data to estimate key MetS components were included. Sex-stratified logistic regression identified baseline variables associated with MetS.

Results
The sample included 1543 participants; 71% were female and the mean age was 54 (SD 15) years. MetS prevalence was higher in men 188 (42%) than women 288 (26%, P < 0.0001) and increased with age. Frequent MetS components in men were hypertension (62%), impaired glucose tolerance (IGT, 40%), obesity (36%), and low high-density lipoprotein cholesterol (36%). Postmenopausal women had greater frequency of hypertension (65%), IGT (32%), and high triglycerides (21%) compared with premenopausal women (P < 0.001). In multivariate analysis, MetS was negatively associated with seropositivity and pulmonary disease in men. Increasing age was associated with MetS in women. In postmenopausal women, corticosteroid use was associated with MetS. Psychiatric comorbidity was associated with MetS in premenopausal women. MetS status was not explained by disease activity or core RA measures.

The characteristics and associations of MetS differed in men and women with ERA. Sex differences, including postmenopausal status, should be considered in comorbidity screening. With this knowledge, the interplay of MetS, sex, and RA therapeutic response on cardiovascular outcomes should be investigated.
Relations:
Content
References
(16)
Diseases
(6)
Conditions
(2)
Drugs
(2)
Chemicals
(1)
Genes
(1)
Processes
(2)
Similar articles
Articles by the same authors
Discussion board
ACR Open Rheumatol 1(9): 535-541

Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis

+6 authors

Supporting information

Sinai Health System, University of Toronto, CA,
Dalla Lana School of Public Health, University of Toronto, Toronto CA,
McGill University, Montreal CA,
Western University, London CA,
Université de Sherbrooke, Sherbrooke CA,
Université de Laval, Quebec CA,
University of Calgary, Calgary CA,
Southlake Regional Health Center, Newmarket CA,
University of Manitoba, Winnipeg CA,
Johns Hopkins School of Medicine, Baltimore USA,
Hospital for Special Surgery, Weill Cornell Medical College, New York USA,
B. Kuriya, Email: ac.metsyshtlaehianis@ayiruk.eednib.
Corresponding author.
Address correspondence to Bindee Kuriya, MD, SM, FRCPC, Department of Medicine, University of Toronto, Division of Rheumatology Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 60 Murray Street, Room 2‐008, Toronto, Ontario M5T 3L9, Canada. E‐mail: ac.metsyshtlaehianis@ayiruk.eednib.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Significance &amp; Innovations
Click here for additional data file.(171K, doc)

Notes

The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada (founding sponsors since January 2007), AbbVie Corporation since 2011, Medexus Inc. since 2013, Eli Lilly Canada since 2016, Merck Canada since 2017, and Sandoz Canada, Biopharmaceuticals since 2019. Previously funded by Hoffmann‐LaRoche and Janssen Biotech from 2011‐2016, UCB Canada and Bristol‐Myers Squibb Canada from 2011‐2018, and Sanofi Genzyme from 2016‐2017.

Dr. Kuriya acted as a consultant for Abbvie, Pfizer, Sanofi Genzyme, Eli Lilly, Amgen (less than $10,000); received funding from Abbvie/Sanofi Genzyme/Pfizer (more than $10,000). Dr. Pope maintained consulting relationships with AbbVie, Actelion, Amgen, Bayer, Bristol‐Myers Squibb, Celtrion, Genzyme, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, UCB Canada Inc. (less than $10,000). Dr. Boire served on the advisory boards for Amgen, Bristol‐Myers Squibb, Eli Lilly, Janssen, Pfizer; received speaker fees from Merck, Bristol‐Myers Squibb, Pfizer (less than $10,000). Dr. Bessette received funding for research from Amgen, Bristol‐Myers Squibb, Janssen, Roche, UCB Canada Inc., AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis (more than $10,000); maintained consulting agreements/advisory board membership with Amgen, Bristol‐Myers Squibb, Janssen, Roche, UCB Canada Inc., AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis (less than $10,000); speaker honoraria agreements with Amgen, Bristol‐Myers Squibb, Janssen, Roche, UCB Canada Inc., AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis (less than $10,000). Dr. Thorne maintained consulting agreements/advisory board membership with Amgen, Bristol‐Myers Squibb, Janssen, Roche, UCB Canada Inc., AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis (less than $10,000). Dr. Hitchon received research funding from Pfizer and UCB Canada Inc. (more than $10,000). Dr. Bartlett acted as a consultant for Pfizer, UCB Canada Inc., Lilly, Novartis (less than $10,000). Dr. Keystone received funding for research from AbbVie, Amgen, Bristol‐Myers Squibb, F. Hoffmann‐La Roche Inc, Gilead, Janssen Inc., Lilly Pharmaceuticals, Pfizer, Sanofi‐Aventis (more than $10,000); maintained consulting agreements/advisory board membership with AbbVie, Amgen, AstraZeneca Pharma, Biotest, Bristol‐Myers Squibb, Celltrion, Crescendo Bioscience, F. Hoffmann‐La Roche Inc., Genentech Inc., Gilead, Janssen Inc., Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, UCB Canada Inc. (less than $10,000); and speaker honoraria agreements with Amgen, AbbVie, Bristol‐Myers Squibb, F. Hoffmann‐La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme, UCB Canada Inc. (less than $10,000). Dr. Bykerk acted as a consultant for Amgen, Bristol‐Myers Squibb Company, Sanofi‐Genzyme/Regeneron, Pfizer Pharmaceuticals, UCB Canada Inc. (less than $10,000). No other disclosures or conflicts of interest relevant to this article were reported by any author.

Notes

References

  • 1. Aviña‐Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta‐analysis of observational studies. Arthritis Rheum 2008;59:1690–7. [[PubMed]
  • 2. Kerekes G, Nurmohamed MT, González‐Gay MA, Seres I, Paragh G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 2014;10:691–6. [[PubMed]
  • 3. Hallajzadeh J, Safiri S, Mansournia MA, Khoramdad M, Izadi N, Almasi‐Hashiani A, et al. Metabolic syndrome and its components among rheumatoid arthritis patients: a comprehensive updated systematic review and meta‐analysis. PLoS One 2017;12:e0170361.
  • 4. Pucci G, Alcidi R, Tap L, Battista F, Mattace‐Raso F, Schillaci G. Sex‐ and gender‐related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res 2017;120:34–42. [[PubMed]
  • 5. Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi‐Hashiani A, Ayubi E, et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta‐analysis on observational studies. Menopause 2018;25:1155–64. [[PubMed]
  • 6. Hitchon CA, Boire G, Haraoui B, Keystone E, Pope J, Jamal S, et al. Self‐reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. Rheumatology (Oxford) 2016;55:1751–62. [[PubMed]
  • 7. Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross‐sectional study. Arthritis Res Ther 2010;12:R218.
  • 8. Müller R, Kull M, Põlluste K, Aart A, Eglit T, Lember M, et al. The metabolic profile in early rheumatoid arthritis: a high prevalence of metabolic obesity. Rheumatol Int 2017;37:21–7. [[PubMed]
  • 9. Parra‐Salcedo F, Contreras‐Yáñez I, Elías‐López D, Aguilar‐Salinas CA, Pascual‐Ramos V. Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti‐rheumatic drugs: the complex relationship between MetS and disease activity. Arthritis Res Ther 2015;17:34.
  • 10. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48.
  • 11. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, et al. Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2016;32:569–88. [[PubMed]
  • 12. Wong LE, Huang WT, Pope JE, Haraoui B, Boire G, Thorne JC, et al. Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort. Arthritis Care Res (Hoboken) 2015;67:616–23. [[PubMed]
  • 13. Bilecik NA, Tuna S, Samancı N, Balcı N, Akbaş H. Prevalence of metabolic syndrome in women with rheumatoid arthritis and effective factors. Int J Clin Exp Med 2014;7:2258–65.
  • 14. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010;65:262–6. [[PubMed]
  • 15. Matta J, Hoertel N, Kesse‐Guyot E, Plesz M, Wiernik E, Carette C, et al. Diet and physical activity in the association between depression and metabolic syndrome: Constances study. J Affect Disord 2019;244:25–32. [[PubMed]
  • 16. Cho SJ, Lee HJ, Rhee SJ, Kim EY, Kim KN, Yoon DH, et al. The relationship between visceral adiposity and depressive symptoms in the general Korean population. J Affect Disord 2019;244:54–9. [[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.